MFY.F Mochida Pharmaceutical Co. Ltd
- Market cap
- EUR 653M
- P/E
- 11.2x
- P/B
- 0.80x
- ROE
- 9.4%
- Dividend yield
- 2.65%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is MFY.F undervalued?
Graham numberMFY.F trades 37.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mochida Pharmaceutical Co. Ltd fundamental analysis
No fundamental analysis for Mochida Pharmaceutical Co. Ltd yet.
Mochida Pharmaceutical Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mochida Pharmaceutical Co. Ltd
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatologists, psychiatry, and gastroenterological, including Realda and Collagen for the treatment of ulcerative colitis; Goofis and Movicol for the treatment of chronic constipation; interstitial pulmonary hypertension for the treatment of pulmonary arterial hypert…
Full company profileMochida Pharmaceutical Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mochida Pharmaceutical Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 97.4B | 107B | 110B | 102B | 103B | 110B | 103B | 103B | 105B | 117B | 129B |
| Gross Profit | 56.3B | 53.6B | 54.2B | 51.9B | 54.8B | 59.6B | 55.1B | 52.1B | 53.8B | 56.3B | 60.2B |
| Operating Income | 11.4B | 11.7B | 10.6B | 8.81B | 12.0B | 14.4B | 8.51B | 5.80B | 8.13B | 10.1B | 14.2B |
| EBITDA | - | 14.7B | 14.6B | 11.5B | 14.7B | 17.1B | 11.7B | 8.97B | 11.0B | 14.2B | 18.5B |
| Net Income | 8.53B | 9.02B | 8.44B | 4.60B | 8.59B | 10.6B | 6.65B | 4.55B | 5.69B | 7.90B | 13.4B |
| EPS | 215 | 227 | 215 | 119 | 224 | 281 | 182 | 128 | 160 | 223 | 382 |
| Balance Sheet | |||||||||||
| Total Assets | 148B | 155B | 159B | 157B | 162B | 163B | 159B | 159B | 160B | 183B | 185B |
| Total Liabilities | 36.5B | 35.4B | 33.9B | 36.8B | 34.8B | 34.5B | 32.1B | 30.8B | 29.4B | 42.4B | 42.6B |
| Shareholders' Equity | 112B | 120B | 125B | 121B | 127B | 129B | 127B | 128B | 131B | 140B | 142B |
| Cash & Short-term Investments | 46.3B | 45.7B | 51.0B | 53.3B | 54.5B | 48.4B | 47.0B | 33.3B | 45.2B | 28.1B | 25.6B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 5.58B | 3.28B | 12.6B | 9.35B | 9.20B | 7.46B | 7.30B | -7.48B | 9.35B | -7.35B | - |
| Capital Expenditure | 1.11B | 1.10B | 1.37B | 1.96B | 1.94B | 2.99B | 2.17B | 2.30B | 2.16B | 2.70B | 0.00 |
| Free Cash Flow | - | 2.19B | 11.2B | 7.39B | 7.26B | 4.36B | 5.13B | -9.78B | 7.19B | -10.0B | - |
| Ratios | |||||||||||
| ROE | 7.6% | 7.5% | 6.7% | 3.8% | 6.8% | 8.2% | 5.2% | 3.6% | 4.3% | 5.6% | 9.4% |
| ROA | 5.7% | 5.8% | 5.3% | 2.9% | 5.3% | 6.5% | 4.2% | 2.9% | 3.6% | 4.3% | 7.3% |
| Net Profit Margin | 8.8% | 8.5% | 7.7% | 4.5% | 8.3% | 9.6% | 6.4% | 4.4% | 5.4% | 6.8% | 10.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Mochida Pharmaceutical Co. Ltd dividends
- Dividend yield
- 2.65%
- Forward dividend
- 0.48 EUR
- Payout ratio
- 35.9%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 2.84B | 80 | 35.9% |
| 2025 | JPY 2.84B | 80 | 49.9% |
| 2024 | JPY 2.89B | 81 | 63.5% |
| 2023 | JPY 3.37B | 92 | 50.7% |
| 2022 | JPY 3.45B | 92 | 32.6% |
| 2021 | JPY 3.10B | 81 | 36.1% |
| 2020 | EUR 3.34B | 86 | 72.6% |
| 2019 | EUR 3.53B | 90 | 41.8% |
| 2018 | EUR 3.42B | 86 | 37.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Mar 27, 2019.
Who owns Mochida Pharmaceutical Co. Ltd
- Insiders 36.33%
- Institutions 14.17%
- Public & others 49.51%
- Shares outstanding 35.1M
- Free float 22.9M
Mochida Pharmaceutical Co. Ltd company profile
- Company name
- Mochida Pharmaceutical Co. Ltd
- Ticker
- MFY.F
- ISIN
- JP3922800002
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,479
- Fiscal year end
- March
- Address
- 7, Yotsuya 1-chome, Shinjuku, Japan, 160-8515
- Phone
- 81 3 3358 7211
- Website
- mochida.co.jp
About Mochida Pharmaceutical Co. Ltd
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatologists, psychiatry, and gastroenterological, including Realda and Collagen for the treatment of ulcerative colitis; Goofis and Movicol for the treatment of chronic constipation; interstitial pulmonary hypertension for the treatment of pulmonary arterial hypertension; Treprospermid, for pulmonary hypertension associated with ulcerative lung disease; Uris, for gout and hyperuricemia; and Clorox, for ulcerative colitis; Epadel for hyperlipidemia and obstructive arteriosclerosis; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker antihypertensive drug; Heparin Na anticoagulants; and Onboard, ulcerative colitis and Crohn's disease treatment agents. In addition, it develops medical devices, including dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for adhesion prevention material. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products, as well as academic research and marketing. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Shinjuku, Japan.
Mochida Pharmaceutical Co. Ltd management
10- Mr. Naoyuki MochidaPresident & Chairperson · born 1958
- Masaaki YokosukaExecutive Officer and Legal & Compliance Manager
- Mr. Junichi Sakaki Ph.D.Senior Executive Managing Officer & Representative Director · born 1960
- Tomokazu MatsusueManaging Executive Officer & Head of Business Development Division
- Hitoshi MizunoManaging Executive Officer & GM of Medical Device Product Development
- Junichi MakinoExecutive Officer Deputy Head of Pharmaceutical Sales Division
- Taiji HayanoGM of Pharmaceutical Development Division & Managing Executive Officer
- Kenji MiyajimaDirector & Managing Executive Officer · born 1967
- Motoi MitsuishiSenior Executive Managing Officer & Representative Director · born 1963
- Yoshitaka Hosaka Ph.D.Executive Managing Officer & Head of Business Promotion Headquarters